Retatrutide is not just tirzepatide with glucagon bolted on. When Lilly designed it, they changed the entire receptor profile — cranking GIP from 1× native (tirzepatide) to 2× native, bumping GLP-1 from 0.2× to 0.5×, and adding glucagon at 0.2×. The redesign reflects a specific lesson from tirzepatide's clinical data: GIP at 1× native works brilliantly in non-diabetic obesity but gets blunted in type 2 diabetes, where the "incretin defect" impairs GIP signaling at the receptor level. Retatrutide was engineered to push through that defect with stronger GIP and to bypass it entirely through glucagon, which tells the liver to burn stored fat regardless of diabetic status.
Phase 3 obesity trials are ongoing. The weight loss numbers should hold or improve — the phase 2 curve hadn't plateaued at 48 weeks, versus 72 for tirzepatide's SURMOUNT program.
The more interesting unknown is body composition. The only DXA data so far (63:37 fat-to-lean) comes from the T2D substudy, where GIP is blunted. In non-diabetic populations, where retatrutide's 2× GIP can work at full strength, that ratio could shift meaningfully — though the glucagon component is inherently catabolic, which may cap the improvement.
| At a Glance | |
|---|---|
| Cost & access | Investigational — accessible via clinical trials or research-grade suppliers; not available through pharmacies or insurance. |
| Starting dose | 1–4 mg total per week. Many users stay at 1–2 mg for recomp goals — clinical trial doses (8–12 mg) target morbid obesity. Use our GLP-1 dosing tool to optimize injection frequency and stabilize plasma levels to reduce GI side effects. |
| Dose titration | Increase every 2–4 weeks based on response and tolerability. Find the effective range for your goals rather than chasing clinical maximums. |
| Protocol | Weekly injection(s), continuous. Heart rate monitoring essential as doses increase. |
| Results timeline | Appetite suppression in weeks 1–4, meaningful weight loss after week 4, and further acceleration in weeks 12–24. Clinical trials also showed 84% liver fat reduction in 48 weeks. |
| Side effects | GI issues during titration (nausea, fullness). Heart rate increase of 2–7 bpm at higher doses. Jump to managing side effects. |
| Regulatory status | Investigational — FDA Phase 3 trials ongoing. |
| Best stacked with | NAD+ — mitigate energy crashes and promote fat oxidation. See beginner stack with NAD+. MOTS-c + L-Carnitine to promote fat-as-fuel metabolism. AOD-9604 for enhanced stubborn fat loss. Tesamorelin as the foundation of lean mass preservation during rapid weight loss. See also Dual-Axis Recomp. |
Comparing options? Try the GLP-1 Comparison tool — or explore deep dives on Tirzepatide (Mounjaro/Zepbound), Semaglutide (Ozempic/Wegovy), and Oral GLP-1s (Rybelsus/Orfoglipron).
What Retatrutide Is
A single peptide that activates three receptors: GLP-1, GIP, and glucagon. Three jobs at once:
- Moderate appetite and slow gastric emptying (GLP-1)
- Improve insulin efficiency and engage fat tissue (GIP)
- Directly tell the liver to burn stored fat (glucagon)
Result: appetite control + metabolic efficiency + aggressive liver/visceral fat targeting.
Given as weekly injection. Still in phase 3 trials — not available for routine care.
How Retatrutide Works
Retatrutide has the strongest GIP signal (2x) of any approved or investigational incretin. Moderate GLP-1 (0.5x) provides appetite control without the intense nausea of full GLP-1 agonists. The attenuated glucagon (0.2x) is enough to aggressively target liver and visceral fat without the hyperglycemic effects of full glucagon activation.
| Receptor | What it does | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|---|
| GLP-1R | Appetite suppression, gastric slowing | 0.5× | 0.2× | 1.0× |
| GIPR | Insulin efficiency, fat metabolism | 2.0× | 1.0× | — |
| GCGR | Liver fat oxidation, energy expenditure | 0.2× | — | — |
GLP-1: Slows gastric emptying, strengthens satiety, boosts insulin when glucose is high. Appetite moderates without extreme hunger.
GIP: Improves insulin efficiency, engages fat cells in energy use. Same pathway that gives tirzepatide its body-composition advantages.
Glucagon: Sends a direct "burn fat" signal to the liver. Glucagon is insulin's counter-signal—where insulin stores, glucagon releases. This drives liver fat reductions beyond what weight loss alone explains.
The trade-off: Glucagon also increases heart rate and is linked to benign arrhythmias in trials. Cardiac monitoring is essential.
Retatrutide Weight Loss Results
Obesity trials
At 8–12 mg weekly over ~12 months, average losses reach 20–25%. Many hit 15%+; a meaningful subset approaches or exceeds 30%.
| Study | Population | Duration | Top dose | Mean weight loss |
|---|---|---|---|---|
| Phase 2 obesity | Obesity/overweight (no diabetes) | 48 weeks | 8–12 mg | 22–24% |
| Phase 2 T2D | Type 2 diabetes | 36 weeks | 8–12 mg | ~17% |
| Obesity + MASLD | Obesity + liver disease | 48 weeks | 8–12 mg | Similar + aggressive liver fat reduction |
Trajectory:
- Early weeks: low-dose adaptation
- Weeks 12–24: loss accelerates at maintenance doses
- Weeks 24–48: curves continue down as liver/visceral fat responds
Why the T2D numbers look lower
The headline 24.2% comes from the obesity arm (non-diabetic). The T2D trial showed ~17% at 36 weeks — lower, but context matters. Every incretin drug shows roughly 40–50% less weight loss in diabetic populations at comparable doses. Tirzepatide at the same 15 mg dose produced ~13% in T2D (SURPASS-2, 40 weeks) versus 22.5% in non-diabetic obesity (SURMOUNT-1, 72 weeks). Retatrutide's gap is closer to 30%, despite the T2D trial being 12 weeks shorter, which suggests the stronger GIP and the glucagon channel are partially compensating for the incretin defect rather than being defeated by it.
The reason is biological: in type 2 diabetes, GIP signaling is impaired — not just for insulin, but for the adipose tissue effects that drive fat-selective loss. GIP has to repair broken pathways rather than supercharge healthy ones. Tirzepatide's 1× GIP couldn't overcome this in head-to-head T2D trials — it showed nearly identical fat:lean ratios to semaglutide (~86:14 vs ~86:14). Retatrutide's stronger GIP plus a glucagon pathway that sidesteps the problem entirely may explain why it still hit ~17% in T2D at a shorter duration than tirzepatide managed ~13%.
Liver fat (MASLD)
Retatrutide's standout data. Liver fat reductions far exceed semaglutide or tirzepatide:
| Drug | Mechanism | Liver fat reduction | Source |
|---|---|---|---|
| Semaglutide | GLP-1 only | ~30% | Phase 2 NAFLD trials |
| Tirzepatide | GLP-1 + GIP | ~47% | SYNERGY-NASH (phase 2) |
| Retatrutide | GLP-1 + GIP + glucagon | ~86% | Phase 2 MASLD cohort |
Note: These are phase 2 results from different trial populations. Head-to-head comparisons don't exist yet.
Retatrutide targets liver and visceral fat in ways older drugs don't. This advantage must be weighed against its cardiac signal.
Body composition
The only DXA body composition data comes from the T2D substudy (Lancet 2025) — 189 participants, scans at baseline and 36 weeks (not the full trial duration):
- Fat:lean ratio of ~63:37 — roughly 63% of weight lost was fat, 37% lean mass
- Very large absolute fat-mass losses (up to −26% fat mass at 8 mg)
- The study noted "the proportion of lean mass loss to weight loss was similar to other obesity treatments"
For context, tirzepatide shows 75:25 in non-diabetic obesity (SURMOUNT-1) but ~87:13 in T2D head-to-head trials — nearly identical to semaglutide's ~86:14 in the same study. The incretin defect flattens GIP-mediated body composition advantages in diabetic populations. Retatrutide's 63:37 in T2D, while not as favorable as tirzepatide's non-diabetic numbers, comes from a population where GIP signaling is impaired and over a shorter measurement window.
Key evidence gap: No body composition data exists for retatrutide in non-diabetic populations. Given that retatrutide's GIP is 2× native (vs tirzepatide's 1×), the ratio could improve meaningfully when GIP receptors are functioning normally — though the glucagon component's catabolic pressure works against this. This is the most important unknown for the phase 3 program.
For strategies to preserve muscle on any GLP-1, see the muscle preservation guide.
Dosing (Trial-Based)
Important: Retatrutide is investigational. This reflects trial protocols, not clinical recommendations.
Titration pattern (Phase 2)
| Phase | Weeks | Dose | Effect |
|---|---|---|---|
| Start | 1–4 | 1–2 mg | Baseline adaptation, GI/cardiac assessment |
| Build | 5–12 | 4–6 mg | Appetite reduction, early weight loss |
| Effect | 13–24 | 8 mg | Significant loss, liver fat reduction |
| Maintenance | 25–48 | 8–12 mg | Sustained effect |
Dose bands
| Band | Dose | Expected Effect |
|---|---|---|
| Low | 1–2 mg | Tolerance testing, minimal weight change |
| Moderate | 4–6 mg | ~10–15% weight loss, moderate liver fat reduction |
| High | 8–12 mg | ~20–25%+ weight loss, ~80–90% liver fat reduction |
Key principles
Using compounded retatrutide? Use the peptide calculator to determine exact injection volumes from your vial concentration. Splitting your weekly dose across multiple injections using our dosing optimizer stabilizes blood plasma levels and reduces the peak-trough swings that drive GI side effects.
- Start low, go slow: Begin at 1 mg, increase every 2–4 weeks if tolerated
- Cardiac monitoring essential: HR increases are dose-dependent (+2–3 bpm at low doses, up to +6–7 bpm at 12 mg)
- Individualize: Some achieve adequate results at 4–6 mg; higher isn't always better if cardiac signals emerge
Side Effects and Safety
GI effects (common, similar to other GLP-1 drugs)
- Nausea and early fullness
- Vomiting or reflux (especially after large/high-fat meals)
- Diarrhoea or constipation
Managed with paced titration, meal adjustments, and short-term GI support.
Cardiac signal (unique to retatrutide)
| Effect | Incidence | Dose sensitivity |
|---|---|---|
| Resting HR increase | +2–3 bpm (low doses) to +6–7 bpm (high doses) | Very high |
| Benign arrhythmias | ~4–14% vs ~2–3% placebo | High |
Increases appear early, peak, then partially attenuate. Serious arrhythmias not dominant in published data, but cardiac history and monitoring are essential.
Other concerns
Same as broader GLP-1 class: gallbladder effects, pancreatitis risk, rapid weight loss consequences. Magnified here due to drug potency.
Monitoring
Beyond the scale:
- Weight, waist, body composition (confirm loss is from fat)
- Fasting glucose, HbA1c, fasting insulin
- Liver enzymes and imaging (especially MASLD phenotypes)
- Lipid panels and CV risk markers
- Resting HR and rhythm — ECG in higher-risk individuals
Goal: confirm meaningful risk reduction (especially liver/visceral) without new cardiac or metabolic problems.
Retatrutide vs Tirzepatide
Both are multi-agonist incretin drugs with striking results, but their profiles differ.
Weight loss: Retatrutide's 24% at 48 weeks (non-diabetic, no plateau) edges tirzepatide's 22.5% at 72 weeks — but the comparison is imperfect (different durations, phase 2 vs phase 3). In T2D, retatrutide hit ~17% at 36 weeks versus tirzepatide's ~13% at 40 weeks at the same dose. The smaller gap in T2D likely reflects retatrutide's stronger GIP (pushing through impaired signaling) and glucagon (bypassing it via the liver). Tirzepatide has far more data and clearer body-composition numbers in non-diabetic populations.
Liver fat: Retatrutide's glucagon component drives ~86% reductions vs ~47% for tirzepatide. For liver/visceral-fat–dominated risk, retatrutide is compelling if cardiac trade-offs are acceptable.
Safety/status: Tirzepatide is approved with no HR signal. Retatrutide is investigational with a cardiac signal that may restrict use. For most people today, tirzepatide is the practical choice.
| Drug | Receptors | Liver fat reduction | HR effect | Fat:lean ratio |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~30%† | None | ~60:40† |
| Tirzepatide | GLP-1 + GIP | ~47%† | None | ~75:25‡ |
| Retatrutide | GLP-1 + GIP + glucagon | ~86%† | Yes (dose-dependent) | ~63:37† |
†Phase 2 data, mostly T2D/MASLD populations. ‡SURMOUNT trials, non-diabetic obesity population.
Trade-off: retatrutide pushes liver fat harder, but with a cardiac signal and limited body-composition data in non-diabetic populations.
Who Retatrutide Might Be For
Not yet available for routine care. If approved, likely appropriate for:
Good fit:
- Severe MASLD or high liver-fat burden
- Visceral-fat–dominated phenotypes (e.g., South Asian patterns, family history)
- Tirzepatide already tried and plateaued, but substantial loss still needed
Less appropriate:
- Liver fat is not the dominant risk
- Cardiac history or limited monitoring capacity
- Older GLP-1 or dual-agonist drugs haven't been fully tried
Retatrutide looks like a specialized tool for high-risk metabolic phenotypes, not a general-purpose weight-loss drug.
Reading the Data
All retatrutide data are early — phase 2 trials with small samples. The weight loss headlines (24.2%) come from a non-diabetic obesity trial (338 participants, 48 weeks). The body composition data (63:37 fat:lean) comes from a separate T2D trial (189 participants, 36-week DXA). The liver fat data (~86% reduction) comes from a MASLD substudy. These are different populations, different durations, and can't be directly cross-compared.
- Weight-loss ranges reflect structured trial conditions, not guarantees
- Body composition ratios may improve in non-diabetic populations (where GIP works fully) — but we don't have that data yet
- Liver-fat changes may not translate to lower-risk users
- Cardiac signals may change as larger cohorts are studied
Retatrutide changes the ceiling for liver/visceral fat and may narrow the efficacy gap between diabetic and non-diabetic populations through its redesigned receptor profile, but it remains an investigational tool, not a settled answer.
FAQ
How much weight can you lose on retatrutide?
Average 20–25% over ~12 months at higher doses. Some reach or exceed 30%. Assumes structured titration and close monitoring.
How much can retatrutide reduce liver fat?
~86% in MASLD trials — substantially more than semaglutide (~30%) or tirzepatide (~47%). Glucagon component actively mobilizes hepatic fat rather than relying on indirect effects from weight loss.
Is retatrutide better than tirzepatide?
Depends on the problem. For broad obesity today, tirzepatide has stronger data, is approved, and lacks a cardiac signal. For liver/visceral-fat–dominated risk, retatrutide's early results are more powerful but come with cardiac trade-offs.
In type 2 diabetes specifically, retatrutide may have a structural advantage — its stronger GIP (2× vs 1× native) pushes harder against the incretin defect that blunts tirzepatide's GIP benefits in diabetics, and its glucagon channel bypasses impaired incretin signaling entirely via direct hepatic action. But this is phase 2 data; phase 3 will tell us whether the advantage holds at scale.
When might retatrutide be approved?
Phase 3 underway, but timelines depend on outcomes and safety findings. Even if favorable, initial indications may focus on high-risk groups rather than general weight management.
What are the side effects of retatrutide?
GI side effects are similar to other incretin drugs: nausea, vomiting, diarrhea, and constipation, especially during titration. The unique concern is cardiac effects—resting heart rate increases of 2–7 bpm depending on dose, and benign arrhythmias in 4–14% of trial participants versus 2–3% on placebo. These effects typically stabilize but require monitoring, especially in people with cardiac history.
How is retatrutide different from semaglutide and tirzepatide?
Retatrutide hits three receptors instead of one or two. Semaglutide works through GLP-1 only; tirzepatide adds GIP. Retatrutide adds glucagon on top of both, which directly tells the liver to burn stored fat.
This triple action drives more aggressive liver fat reduction (~86% vs ~47% for tirzepatide) but comes with heart rate increases that the other drugs don't cause. For detailed lipid panel comparisons, see the GLP-1 cholesterol guide.
Is retatrutide safe? What do the trials show?
Phase 2 trials show a favorable overall safety profile for GI effects, but the cardiac signal is the key question mark. Heart rate increases and benign arrhythmias occur more frequently than placebo. No serious cardiac events dominated published data, but long-term cardiovascular outcomes won't be known until phase 3 completes. For now, it's considered reasonably safe with appropriate monitoring—but it's investigational, not proven.
How do I get retatrutide before FDA approval?
Currently, the main routes are clinical trials and research-grade suppliers. Clinical trials offer the most oversight but have strict enrollment criteria.
Research peptide suppliers sell retatrutide, but quality varies widely, there's no regulatory oversight, and you're essentially experimenting on yourself. Some specialty clinics offer it under "research" frameworks. None of these are equivalent to an approved drug from a pharmacy.
What is the recommended retatrutide dosage and protocol?
Retatrutide is injected subcutaneously once per week with a gradual titration. Based on phase 2 trials: start at 1–2 mg weekly for weeks 1–4, increase to 4–6 mg for weeks 5–12, then 8 mg for weeks 13–24, with a maintenance range of 8–12 mg from week 25 onward. A full protocol runs approximately 48 weeks.
Hold each dose increase for at least 2–4 weeks to assess tolerability. Moderate doses (4–6 mg) produce significant weight loss; high doses (8–12 mg) push toward maximum liver fat reduction but increase cardiac effects. Retatrutide is used continuously without cycling.
Cardiac monitoring is essential — check resting heart rate regularly, especially above 8 mg. Liver enzymes and metabolic panels at baseline and every 3 months. Most people don't need maximum doses; find the level that produces results with acceptable side effects. Note that it remains investigational — no approved dosing exists, and these ranges come from phase 2 trial protocols.
Does retatrutide need to be cycled or can I take it continuously?
Retatrutide does not need to be cycled based on available trial data — participants used it continuously for 48 weeks. Like other GLP-1 agonists, the effects depend on ongoing use. However, retatrutide is investigational with no long-term safety data beyond trial durations, so protocols are provisional. The glucagon component raises heart rate modestly, which is one reason cardiac monitoring matters more here than with semaglutide or tirzepatide.
Does retatrutide affect heart rate?
Yes, and this is the main safety differentiator from tirzepatide or semaglutide. Resting heart rate increases by 2–3 bpm at low doses and up to 6–7 bpm at 12mg weekly. Benign arrhythmias (palpitations, skipped beats) occur more frequently than placebo. These effects appear early and partially attenuate over time, but cardiac monitoring is essential—especially for anyone with pre-existing heart conditions.
Can I use retatrutide for diabetes?
Retatrutide is being studied for type 2 diabetes and shows strong glucose-lowering effects — up to 82% of participants reached HbA1c < 6.5% in the phase 2 T2D trial, with ~17% weight loss at 36 weeks.
Retatrutide was specifically designed with stronger GIP signaling (2× native vs tirzepatide's 1×) to push through the impaired GIP response that characterizes T2D, plus glucagon for direct liver fat mobilization that bypasses impaired incretin pathways entirely. However, it's not approved for any indication yet. If you have diabetes and want an incretin drug now, tirzepatide (Mounjaro) is the approved option with excellent HbA1c data.
How should retatrutide be stored?
Research-grade retatrutide typically comes as lyophilized powder requiring reconstitution. Store the powder refrigerated (2–8°C) or frozen for long-term storage. Once reconstituted with bacteriostatic water, keep refrigerated and use within 4–6 weeks.
Never freeze reconstituted peptide. If you're in a clinical trial, follow the specific storage instructions provided—trial formulations may differ from research-grade products.
Related Topics
- Complete GLP-1 Comparison — compare all three GLP-1 drugs
- Tirzepatide Guide — the approved dual-agonist for most people today
- Semaglutide Guide — the established GLP-1 benchmark
- NAD+ Guide — cellular energy support that complements metabolic interventions
- Reconstitution Guide — How to prepare research-grade retatrutide vials
References
- Retatrutide phase 2 obesity trial — non-diabetic (Jastreboff et al., NEJM 2023): NEJM article (10.1056/NEJMoa2301972)
- Retatrutide phase 2 T2D trial (Rosenstock et al., ADA 2023): ADA Meeting News summary
- Retatrutide phase 1b T2D trial (Urva et al., Lancet 2022): Lancet article (S0140-6736(22)02033-5)
- Retatrutide T2D body composition / DXA substudy (Lancet Diabetes Endocrinol 2025): PubMed study (PMID: 40609566)
- Retatrutide MASLD substudy (Nature Medicine 2024): Nature article (s41591-024-03018-2)
- Retatrutide MASLD substudy (PMC full text): PMC article (PMC11271400)
- Retatrutide discovery and receptor pharmacology (Coskun et al., Cell Metabolism 2022): Cell Metabolism (10.1016/j.cmet.2022.07.002)
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.